Home
 
 

Drugs Sector

Hot Stocks in This Sector Johnson & Johnson, Walgreen Company, Abbott Laboratories, Schering-Plough, Elan Corporation, plc, CVS, Merck & Company, Pfizer.
Related Sectors Healthcare, Medical Facilities.
Hot Sectors Investing, Healthcare, Services, Banking, Energy.
View all Sectors

Industries in the Drugs Sector

 

Drugs Upgrades

Date Ticker Analyst Old Rating New Rating
11/09/2009 AZN RBS Hold Buy
11/03/2009 HLF Avondale Securities Market Perfrom Market Outperform
10/28/2009 USNA DA Davidson Neutral Buy
10/15/2009 PRX Barclays Equalweight Overweight

Drugs Downgrades

Date Ticker Analyst Old Rating New Rating
11/09/2009 AZN J.P. Morgan Neutral Underweight
11/06/2009 CAH Jefferies & Co Buy Hold
11/06/2009 CVS William Blair Outperform Market Perform
11/02/2009 GERN Needham & Co Buy Hold

Drugs New Coverages

Date Ticker Analyst Rating
11/05/2009 YMI Merriman Curhan Ford Buy; Intriguing Opportunity
10/30/2009 ALXN Bank of America Neutral
10/30/2009 ALXN Bank of America Neutral
10/30/2009 VRTX Deutsche Bank Buy

Drugs Earnings

Date Ticker Actual Expected Prev Yr Qtr
11/10/2009 JAV -0.11 -0.10 -0.18
11/10/2009 ACET 0.04 0.06 0.18
11/10/2009 RDEA -0.13 -0.53 -0.95
11/10/2009 DUSA -0.02 -0.04 -0.12
View more earnings releases

Drugs Hot Stock Quote

Special Offers

Buy stock for just $4
www.sharebuilder.com

Make the most of Volatility. Stream a free Webcast from The Options Industry Council.
optionseducation.org

Forex trading: Trade with the worldwide leader and most competitive broker!
www.ac-markets.com

Stock of the Day

The Drugs Sector's CVS Caremark (CVS) was InvestorGuide.com's Stock of the Day on 11/5/2009.
CVS is Pained by its Weak Pharmacy Benefits Division
CVS Caremark Corp. is a company that wears many different hats. The company runs a network of over 7,000 CVS drugstores, maintains pharmacy locations within those drugstores, and now also owns a pharmacy benefits company (Caremark). Although these businesses are very closely related, the acquisition of Caremark was questioned by many investors. Investors saw this as a risky move which might help the company, but one which might also cause more pain than it was worth. This quarter, as it has been with every quarter since the acquisition, investors and analysts waited to see if the results would help them determine if this was indeed a good decision or not. And based on the response of the investors after the earnings announcement, they got a very clear answer. Read more

Click here to see the complete Stock of the Day archives!

Subscribe to our Stock
of the Day Newsletter


 
 
Got feedback?
White Spacer
The market in:
: :
White Spacer
White Spacer